We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Selective Use of D-Dimer Test for Deep Vein Thrombosis

By LabMedica International staff writers
Posted on 30 Jan 2013
D-dimer testing based on clinical pretest probability for deep vein thrombosis (DVT) is safe and reduces diagnostic testing compared with checking all patients.

D-dimer testing is sensitive but not specific for DVT and changing the threshold level for a positive test result based on risk for DVT might improve the tradeoff between sensitivity and specificity and reduce the need for testing.

Scientists from McMaster University, (Hamilton, ON, Canada) randomly assigned 1,723 outpatients presenting for the first time with symptoms of DVT to selective testing for D-dimer for patients with low or moderate clinical pretest probability of DVT. More...
Some patients with high clinical pretest probability had venous ultrasonograpy without D-dimer testing and some patients presenting with symptoms had uniform testing. The study groups were all consecutive symptomatic patients with a first episode of suspected DVT from five different hospitals.

Selective testing of 860 patients, defined as d-dimer testing for outpatients with low or moderate clinical pretest probability (C-PTP), where DVT excluded at d-dimer levels of equal to or less than 1.0 µg/mL, a low C-PTP or equal to or less than 0.5 µg/mL, moderate C-PTP. The groups who had venous ultrasonography without d-dimer testing for outpatients with high C-PTP and inpatients, or the 863 uniform testing defined as d-dimer testing for all participants where DVT was excluded at d-dimer levels of less than 0.51 µg/mL.

The incidence of symptomatic venous thromboembolism at three months was 0.5% in both study groups. Selective testing reduced the proportion of patients who required d-dimer testing by 21.8% and reduced the proportion that required ultrasonography by 7.6 % overall and by 21.0% in outpatients with low C-PTP. The authors concluded that a selective d-dimer testing strategy seems as safe as and more efficient than having everyone undergo d-dimer testing when diagnosing a first episode of suspected DVT. The study was published on January 15, 2013, in the journal Annals of Internal Medicine.

Related Links:

McMaster University




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.